Who Developed the Pfizer-BioNTech COVID-19 Vaccine?

Germany’s BioNTech and the U.S. pharmaceutical company Pfizer jointly developed the COVID-19 vaccine marketed as Comirnaty. BioNTech started the vaccine research program and contributed its messenger RNA (mRNA) technology and vaccine candidates. Pfizer helped advance clinical development and brought regulatory, manufacturing, and distribution capabilities to the partnership. In the European Union, BioNTech Manufacturing GmbH holds the marketing authorization for Comirnaty. Pfizer

What Is BioNTech and Who Founded It?

BioNTech is a biotechnology company based in Mainz, Germany. Uğur Şahin, Özlem Türeci, and Christoph Huber founded the company in 2008. Its early work focused on developing new approaches to cancer treatment, including ways to use mRNA in personalized immunotherapies. Şahin and Türeci had already spent years researching how mRNA could be used to help the immune system recognize a target. That work gave BioNTech a platform it could use when it began developing a vaccine against SARS-CoV-2. biontech.com

How Did Pfizer and BioNTech Develop the Vaccine?

BioNTech launched its COVID-19 vaccine program, Project Lightspeed, in January 2020. Pfizer and BioNTech announced their collaboration in March. The companies already had experience working together on an mRNA influenza vaccine project that began in 2018. For COVID-19, they moved several vaccine candidates into early clinical testing and selected BNT162b2 for a larger trial in July 2020. That candidate became Comirnaty. biontech.com

The partnership also divided clinical and regulatory responsibilities. According to BioNTech’s annual filing, Pfizer led clinical development and sought regulatory approval in the United States, while BioNTech took the lead in the European Union. Both companies shared responsibility for manufacturing and supplying the vaccine. These roles explain why both company names appear in references to the Pfizer-BioNTech COVID-19 vaccine. sec.gov

Who Holds the Rights to Comirnaty?

The European Medicines Agency lists BioNTech Manufacturing GmbH as the EU marketing authorization holder. The U.S. Food and Drug Administration also lists that company as the manufacturer in its Comirnaty product record. Marketing authorization identifies the company named on the regulatory approval. The rights to sell and distribute the vaccine are set out in separate commercial agreements. European Medicines Agency (EMA)

In its 2025 annual filing, BioNTech reported that it held marketing and distribution rights in Germany and Türkiye, while Pfizer held those rights across most other markets. Fosun Pharma held rights in mainland China, Hong Kong, Macau, and Taiwan under a separate agreement. BioNTech also granted Pfizer a license covering certain patents, technical know-how, and technology licensed from third parties for use under the collaboration. sec.gov

When Was the Pfizer-BioNTech Vaccine Authorized?

The United Kingdom authorized the vaccine on December 2, 2020. The FDA issued a U.S. emergency use authorization on December 11, 2020, and the EU issued its initial marketing authorization on December 21, 2020. On August 23, 2021, the FDA granted its first approval of a COVID-19 vaccine, with the approved Pfizer-BioNTech product marketed as Comirnaty. The two U.S. dates refer to different regulatory steps in the vaccine’s history. GOV.UK

What Technology Does Comirnaty Use?

Comirnaty uses messenger RNA to deliver instructions for making the spike protein found on the surface of SARS-CoV-2. After vaccination, some cells temporarily make the protein. The immune system recognizes it and produces antibodies and activates immune cells. The body then breaks down the vaccine’s mRNA. The European Medicines Agency’s product overview also describes updated formulations with mRNA instructions for spike proteins from later variants of the virus. European Medicines Agency (EMA)

Sources

Next Article

Who Owns Beko? Arçelik, Koç Holding, and the Brand’s History